Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.
Keywords: AAD; AD; ADHD; American Academy of Dermatology; CDLQI; Children's Dermatology Life Quality Index; DFI; DLQI; Dermatitis Family Impact; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; FLG; GREAT; Global Resource for Eczema Trials; IGA; IL; ISAAC; IgE; International Study of Asthma and Allergies in Childhood; Investigator's Global Assessment; MDC; POEM; Patient-Oriented Eczema Measure; SASSAD; SCORAD; SCORing Atopic Dermatitis; SORT; Six Area, Six Sign Atopic Dermatitis; TARC; TISS; Three-Item Severity Scale; UK; United Kingdom; assessment scales; atopic dermatitis; attention deficit hyperactivity disorder; biomarkers; clinical associations; criteria; diagnosis; filaggrin; immunoglobulin E; interleukin; macrophage-derived chemoattractant; risk factors; strength of recommendation taxonomy; thymus and activation-regulated chemokine.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.